Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS
Clinical trial NCT04449588 · TERMINATED
Trial details
- NCT number
- NCT04449588
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-23
- Primary completion
- 2024-03-26
- Enrollment
- 369
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.